This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Nolla Health Announces Nation's First AI to Issue Initial Prescriptions
-
Accuracy and Safety of Large Language Models in Endometrial Cancer Decision Making: A Case-Based In Silico Benchmarking Study
Emanuele Perrone, et al.. JCO Clinical Cancer Informatics, 2026.
DOI: 10.1200/CCI-26-00142
-
Feature Interaction-Informed Deep Radiomics for Prediction of Distant Metastasis-Free Survival in Head and Neck Cancer
R. Hou, et al..
Weekly News Brief: October 5–9, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of October 5–9, 2026.
This week’s brief covers approval for AI-issued initial acne prescriptions under staged physician oversight in Utah, a benchmarking study that found consumer chatbots too inconsistent and unsafe for unsupervised endometrial cancer decision-making, and a deep radiomics model that improved prediction of distant metastasis from pretreatment CT in head and neck cancer.
To learn more about Nolla Derm, read "Utah Pilot Tests AI-Issued Initial Prescriptions," or see the press release.
For more information on LLMs in oncological decision-making, read "Head-to-Head Benchmarking of Three LLMs in Endometrial Cancer Decision-Making," or see the source report in JCO Clinical Cancer Informatics.
To learn more about OmicsMap, read "Deep Radiomics Framework Predicts Distant Metastasis Using Pretreatment CT in Head and Neck Cancer," or see the conference abstract.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.